Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration

Ekta Rishi, Pukhraj Rishi, Vishal Sharma, Vikram Koundanya, Renu Athanikar

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Aim: To evaluate and compare the efficacy of combination of ranibizumab or bevacizumab with photodynamic therapy (PDT) in treating choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD) on long-term follow-up. Materials and Methods: Of 42 eyes, 18 were treated with bevacizumab (Group A) and 24 with ranibizumab (Group B) in combination with verteporfin PDT. Treatment was initiated after informed consent. Complete ophthalmic examination including optical coherence tomography (OCT) was performed at presentation, 1 month, 3 months, and subsequent follow-up visits. OCT measures used were lesion thickness (LT) of the CNV, retinal thickness above the lesion (RT), and central macular thickness (CMT). Mean follow-up period was 33 months (median 18, range 1-84). Additional treatment on follow-up was left at treating surgeon′s discretion. Results: Visual acuity improved significantly from baseline by 0.3 LogMAR in Group A and 0.26 LogMAR in Group B. LT decreased significantly from 1 st month onward and remained significant at all the subsequent visits, in both the groups. CMT and RT showed a decreasing trend in both the groups. No difference was seen in visual acuity (VA), LT, CMT, and RT between Group A and Group B at any of the visits. The mean number of additional anti-vascular endothelial growth factor injections given postcombination therapy were 1.5 (median 1, range 0-7) injections per eye. Conclusions: PDT in combination with either ranibizumab or bevacizumab was equally effective in preventing vision loss in eyes with wet-Age-related macular degeneration (ARMD). Such combination also reduces the economic burden of the treatment.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalOman Journal of Ophthalmology
Issue number2
StatePublished - Jun 2016
Externally publishedYes


  • Age-related macular degeneration
  • Bevacizumab
  • Choroidal neovascularization
  • Combination therapy
  • Photodynamic therapy
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration'. Together they form a unique fingerprint.

Cite this